Phibro Animal Health Corporation $PAHC Shares Sold by Villanova Investment Management Co LLC

Key Points

• Villanova Investment Management Co LLC has reduced its stake in Phibro Animal Health Corporation by 65.9%, selling 62,365 shares and now holding 32,279 shares worth approximately $689,000.
• Phibro Animal Health reported a quarterly earnings per share of $0.57, exceeding analysts' expectations of $0.52, along with revenue of $378.70 million for the quarter.
• The company recently declared a quarterly dividend of $0.12 per share, with an annualized yield of 1.2%, to be paid to shareholders on September 24th.

Villanova Investment Management Co LLC lowered its position in Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) by 65.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 32,279 shares of the company's stock after selling 62,365 shares during the quarter. Phibro Animal Health comprises about 1.9% of Villanova Investment Management Co LLC's holdings, making the stock its 18th biggest holding. Villanova Investment Management Co LLC owned approximately 0.08% of Phibro Animal Health worth $689,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Phibro Animal Health by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company's stock valued at $260,000 after purchasing an additional 546 shares during the period. Algert Global LLC grew its holdings in shares of Phibro Animal Health by 1.4% in the first quarter. Algert Global LLC now owns 97,612 shares of the company's stock valued at $2,085,000 after purchasing an additional 1,340 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in Phibro Animal Health during the fourth quarter worth about $29,000. National Bank of Canada FI purchased a new position in Phibro Animal Health during the first quarter worth about $30,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in Phibro Animal Health by 9.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 17,668 shares of the company's stock worth $372,000 after buying an additional 1,565 shares during the period. Hedge funds and other institutional investors own 99.34% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on PAHC shares. Zacks Research lowered shares of Phibro Animal Health from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 28th. BNP Paribas raised shares of Phibro Animal Health to a "hold" rating in a research note on Monday, June 16th. BNP Paribas Exane raised shares of Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 target price for the company in a research note on Monday, June 16th. JPMorgan Chase & Co. raised shares of Phibro Animal Health from a "neutral" rating to an "overweight" rating and increased their target price for the stock from $25.00 to $35.00 in a research note on Monday, July 7th. Finally, Morgan Stanley set a $34.00 target price on shares of Phibro Animal Health in a research note on Thursday, August 28th. One analyst has rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Reduce" and an average target price of $28.40.

Insiders Place Their Bets

In related news, CEO Jack Bendheim sold 3,520 shares of the firm's stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $41.29, for a total value of $145,340.80. Following the sale, the chief executive officer owned 41,880 shares of the company's stock, valued at $1,729,225.20. This trade represents a 7.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 50.07% of the stock is currently owned by company insiders.

Phibro Animal Health Stock Down 3.8%

Shares of PAHC traded down $1.57 during mid-day trading on Friday, hitting $39.62. 238,815 shares of the company's stock were exchanged, compared to its average volume of 389,217. The stock's 50-day moving average is $31.98 and its 200-day moving average is $25.53. The company has a market cap of $1.61 billion, a price-to-earnings ratio of 33.58, a P/E/G ratio of 1.22 and a beta of 0.89. Phibro Animal Health Corporation has a fifty-two week low of $16.16 and a fifty-two week high of $41.57. The company has a debt-to-equity ratio of 2.46, a quick ratio of 1.25 and a current ratio of 2.76.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last issued its earnings results on Wednesday, August 27th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.52 by $0.05. The firm had revenue of $378.70 million for the quarter, compared to analysts' expectations of $362.24 million. Phibro Animal Health had a net margin of 3.73% and a return on equity of 32.14%. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. On average, sell-side analysts anticipate that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 24th. Investors of record on Wednesday, September 3rd will be issued a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, September 3rd. This represents a $0.48 annualized dividend and a yield of 1.2%. Phibro Animal Health's dividend payout ratio (DPR) is 40.68%.

Phibro Animal Health Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.